^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATG-027

    i
    Other names: ATG-027
    Associations

    News

    Trials
    Company:
    Antengene
    Drug class:
    PD-L1 inhibitor, B7-H3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    ATG-027, a first-in-class B7-H3/PD-L1 bispecific antibody, shows potent T cell activation capability and in vivo anti-tumor efficacy (SITC 2022)
    ATG-027 can also inhibit the interaction between PD1/PD-L1 to rescue T cell activity suppression. ATG-027’s dual T cell activation function and powerful ADCC, CDC, and ADCP properties contribute to its promising anti-tumor efficacy in preclinical models.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • IL2 (Interleukin 2)
    |
    PD-L1 expression • CD276 overexpression
    |
    ATG-027